{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:53:39Z","timestamp":1791539619778,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejmech.2022.114693","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T22:46:09Z","timestamp":1661294769000},"page":"114693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-9901","authenticated-orcid":false,"given":"Robert K.","family":"Le\u015bniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeremy","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schonemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandresh R.","family":"Gajera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh C.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. William","family":"Langston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Montine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114693_bib1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Sim\u00f3n-S\u00e1nchez","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2022.114693_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2022.114693_bib3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2022.114693_bib4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Pais\u00e1n-Ru\u00edz","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2022.114693_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2022.114693_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.ejhg.5201539","article-title":"Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease","volume":"14","author":"Di Fonzo","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2022.114693_bib7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1212\/01.WNL.0000169023.51764.b0","article-title":"LRRK2 mutations in Parkinson disease","volume":"65","author":"Farrer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2022.114693_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2022.114693_bib9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/humu.20668","article-title":"Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls","volume":"29","author":"Pais\u00e1n-Ru\u00edz","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2022.114693_bib10","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1093\/hmg\/ddi376","article-title":"Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease","volume":"14","author":"Skipper","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2022.114693_bib11","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/hmg\/ddq081","article-title":"Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans","volume":"19","author":"Lesage","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2022.114693_bib12","doi-asserted-by":"crossref","DOI":"10.1042\/AN20090007","article-title":"Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions","volume":"1","author":"Greggio","year":"2009","journal-title":"ASN Neuro"},{"key":"10.1016\/j.ejmech.2022.114693_bib13","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2022.114693_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20070209","article-title":"LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity","volume":"405","author":"Jaleel","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.114693_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2014.1973","article-title":"Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis","volume":"72","author":"Agalliu","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2022.114693_bib16","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1016\/j.ajpath.2020.08.010","article-title":"Somatic mutations in LRRK2 identify a subset of invasive mammary carcinomas associated with high mutation burden","volume":"190","author":"Parrilla Castellar","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2022.114693_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/revneuro-2020-0083","article-title":"Genetic parkinsonisms and cancer: a systematic review and meta-analysis","volume":"32","author":"Sturchio","year":"2021","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114693_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai7795","article-title":"Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease","volume":"10","author":"Hui","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114693_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114080","article-title":"Discovery of G2019S-selective leucine rich repeat protein kinase 2 inhibitors with in vivo efficacy","volume":"229","author":"Le\u015bniak","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114693_bib20","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114693_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1021\/acsmedchemlett.2c00116","article-title":"Discovery of 1H-pyrazole biaryl sulfonamides as novel G2019S-LRRK2 kinase inhibitors","volume":"13","author":"Le\u015bniak","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114693_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114693_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/acs.jmedchem.0c01473","article-title":"Spirocyclic scaffolds in medicinal chemistry","volume":"64","author":"Hiesinger","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114693_bib24","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114693_bib25","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1021\/acs.jmedchem.7b01186","article-title":"Design of leucine-rich repeat kinase 2 (LRRK2) inhibitors using a crystallographic surrogate derived from checkpoint kinase 1 (CHK1)","volume":"60","author":"Williamson","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114693_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/BJ20100483","article-title":"14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization","volume":"430","author":"Nichols","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.114693_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20100784","article-title":"Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)\/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization","volume":"430","author":"Dzamko","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.114693_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1042\/BJ20091035","article-title":"Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease","volume":"424","author":"Nichols","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.114693_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3634","article-title":"Effect of selective LRRK2 kinase inhibition on nonhuman primate lung","volume":"7","author":"Fuji","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114693_bib30","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.xphs.2019.02.005","article-title":"Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration","volume":"108","author":"Feng","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2022.114693_bib31","series-title":"Annual Reports in Medicinal Chemistry","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0065-7743(10)45004-6","article-title":"Chapter 4 - defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure\u2013response relationships","author":"Shaffer","year":"2010"},{"key":"10.1016\/j.ejmech.2022.114693_bib32","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.1021\/acs.jmedchem.0c01243","article-title":"Selective inhibitors of G2019S-LRRK2 kinase activity","volume":"63","author":"Garofalo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114693_bib33","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/mds.28490","article-title":"Differential inhibition of LRRK2 in Parkinson's disease patient blood by a G2019S selective LRRK2 inhibitor","volume":"36","author":"Bright","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2022.114693_bib34","doi-asserted-by":"crossref","first-page":"15914","DOI":"10.1021\/ja108074t","article-title":"A multiligand based Pd catalyst for C-N cross-coupling reactions","volume":"132","author":"Fors","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114693_bib35","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1055\/s-0033-1339118","article-title":"Methanol-promoted borylation of arylamines: a simple and green synthetic method to arylboronic acids and arylboronates","volume":"25","author":"Zhao","year":"2014","journal-title":"Synlett"},{"key":"10.1016\/j.ejmech.2022.114693_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.joc.6b02306","article-title":"The suzuki-miyaura cross-coupling reaction of halogenated aminopyrazoles: method development, scope, and mechanism of dehalogenation side reaction","volume":"82","author":"Jedin\u00e1k","year":"2017","journal-title":"J. Org. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422005955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422005955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:45:48Z","timestamp":1759329948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422005955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":36,"alternative-id":["S0223523422005955"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114693","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114693"}}